Page 2 - Imaging Phenomics News Today

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31st, 2021 Regulatory News: (excluding treasury shares**) (including treasury shares**) (**) pursuant to article 223-11 of the AMFs General Regulations About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment s...

Median Technologies Is Releasing Full Year 2020 Financial Results (audited) as Well as Q1 2021 Business Activity Indicators, Showing a Very Strong Growth 2020 results in line with expectations Acceleration of the growth dynamic in the first quarter of 2021 with revenue of €5.2m, an increase of 86% compared to Q1, 2020. Regulatory News: Median Technologies (Paris:ALMDT) (Euronext Growth ALMDT), whose Board of Directors met on April 6 th, 2021 to approve the consolidated financial statements f...

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares

(2) These two appointments follow a series of first successful achievements for iBiopsy in 2020 and early 2021. Median prepares to launch its iBiopsy product development plan, including regulatory aspects, define its go-to-market strategy then expand its iBiopsy operations globally. Regulatory News: Thomas Bonnefont (Photo: Median Technologies) Median Technologies (ALMDT:PA) (Paris:ALMDT) announced today the appointment of Thomas Bonnefont to the newly created position of Chief Operating and Co...

(1) Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide. First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021. Regulatory News: Median Technologies (ALMDT:PA) (Paris:ALMDT) unveils today a new iBiopsy Clinical Develo...

Press release content from Business Wire. The AP news staff was not involved in its creation. iBiopsy®: Median Technologies Inks a Major Research Collaboration Agreement With the University of California San Diego (UC San Diego) February 9, 2021 GMT Regulatory News: Median Technologies (Paris:ALMDT) (ALMDT:PA) announces today the company has signed a research collaboration agreement with the University of California San Diego (UC San Diego) aimed at carrying out a study that will be used for i...

(1) The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients The collaboration will enable Median to work on a large NASH patient cohort to lead the validation of its iBiopsys AI technology, applied to liver fibrosis characterization The Liver Center at UC San Diego is a world-renowned university and healthcare center for liver diseases, with a focus on Non-Alcoholic Fatty Liver Disease (NAFLD) ...

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares

Regulatory News: Under the liquidity contract entrusted by Median Technologies (Paris:ALMDT) (FR0011049824 ALMDT FP) to Louis Capital Markets|Midcap Partners, the following resources were listed in

Median Technologies Records a 51 % Increase of Its 2020 Annual Revenue (Unaudited Figures) As of December 31, 2020, order backlog of €51.7 million, up 35 compared to December 31, 2019 Cash and cash equivalents of €16.3 million as of December 31, 2020 Regulatory News: Median Technologies (Paris:ALMDT) (ALMDT) today announces strong business activity for the full year 2020 (unaudited figures). In 2020, despite the Covid-19 pandemic and global health crisis, the company continued to grow at a ...